[Congenital toxoplasmosis with hydrocephalus diagnosed in utero: outcome of treatment]. / Toxoplasmose congénitale avec hydrocéphalie diagnostiquée in utero: évolution sous traitement.

BACKGROUND: The neurological outcome for severe toxoplasmosis can be poor despite appropriate management. CASE REPORT: A maternal toxoplasma infection occurred at 16 weeks of amenorrhoea; prenatal diagnosis was attempted at 20 weeks, fetal infection was confirmed by mouse inoculation at the 30th week. Pyrimethamine plus sulfadiazine treatment was initiated. However, at 37 weeks of amenorrhoea, sonographic examination of the fetus detected hydrocephalus. Despite prompt ventriculo-peritoneal shunting after birth and medical treatment of toxoplasmosis, the neurological developmental outcome was complicated and prognosis is poor at 5 years of age. CONCLUSION: This case shows that parents must be carefully warned about risks of a prenatal toxoplasmosis.

[Cryopreservation of isolates of Toxoplasma gondii in cell culture]. / Cryopréservation d'isolats de Toxoplasma gondii en culture cellulaire.

For a better preservation and identification of Toxoplasma gondii isolates, we propose a new method of freezing of toxoplasma growth in THP-1 cell culture. A cystogenic strain isolated from foetal blood has been grown in these cells and frozen in liquid nitrogen. After thawing, toxoplasma recover the same growth rate and morphology in vitro and the same capacity to form brain cysts into mice compared to the initial strains. The freezing of the cell suspension provides a simple and appropriate method for preservation of Toxoplasma gondii within "bank" isolates.

Characterization of AGT1 encoding a general alpha-glucoside transporter from Saccharomyces.

Molecular genetic analysis is used to characterize the AGT1 gene encoding an alpha-glucoside transporter. AGT1 is found in many Saccharomyces cerevisiae laboratory strains and maps to a naturally occurring, partially functional allele of the MAL1 locus. Agt1p is a highly hydrophobic, postulated integral membrane protein. It is 57% identical to Mal61p, the maltose permease encoded at MAL6, and is also a member of the 12 transmembrane domain superfamily of sugar transporters. Like Mal61p, Agt1p is a high-affinity, maltose/proton symporter, but Mal61p is capable of transporting only maltose and turanose, while Agt1p transports these two alpha-glucosides as well as several others including isomaltose, alpha-methylglucoside, maltotriose, palatinose, trehalose and melezitose. AGT1 expression is maltose inducible and induction is mediated by the Mal-activator. The sequence of the upstream region of AGT1 is identical to that of the maltose-inducible MAL61 gene over a 469 bp region containing the UASMAL but the 315 bp sequence immediately upstream of AGT1 shows no significant homology to the sequence immediately upstream of MAL61. The evolutionary origin of the MAL1 allele to which AGT1 maps and the relationship of AGT1 to other alpha-glucoside fermentation genes is discussed.

[Hepatic amebiasis in a metropolis. Apropos of 9 cases]. / L'amibiase hépatique en métropole. A propos de neuf observations.

From 1981 to 1990 nine patients suffering from amebic liver abscess were under observation at the Tours hospital. Hepatic amebiasis is scarce in France. Most of the subjects have stayed in endemic areas. Most of the time patients are male adults suffering from fever and abdominal pains. In most cases the liver ultrasonography shows a single cut of the right lobe with variable and non specific aspects. Once the diagnosis has been given a metronidazole treatment must be prescribed. The diagnosis will be confirmed by serology reactions. Clinical supervision is essential. The clinical effectiveness of the treatment is spectacular. Comparatively it will take about six months until serology reactions and liver ultrasonography get back to normal. Management of hepatic amebiasis need exceptionally echo-guided percutaneous puncture or surgery.